WATCHMAN FLXTM Pro
Left Atrial Appendage Closure Device
featuring HEMOCOAT™ Technology
The WATCHMAN FLX Pro Device is designed with three first-ever features: new HEMOCOAT Technology designed to improve the healing process, radiopaque markers for precise device placement, and a new 40mm size for larger appendages.
Coated for controlled healing
HEMOCOAT Technology is a durable, thromboresistant coating that results in less inflammation and leads to faster, more complete endothelialization.1
Established
PVDF-HFP has a long history of safe use on permanently implanted, blood-contacting medical devices2
Stable
Durable, thin coating encapsulates healing surface of device, maintains pore size and mechanical performance of WATCHMAN FLX platform (<1µm)3
Demonstrated
Impressive performance in challenging preclinical model1
Testing in pre-clinical model has shown remarkable results for faster, more controlled healing1
Next level visibility
Three new radiopaque markers help position and anchor the device with a new level of visual accuracy
Enhance deployment precision
57% increased visibility for more accurate device positioning4
Ensure device
stability
Improved assessment of device anchoring when performing tug test
Enable confident
release
Improved visualization of device orientation and alignment
Close with confidence
A new 40mm size to help treat larger appendages
- Same performance
- Same compression range (10‑30%)
- Same depth requirement
- Saliba et al. JACC: Clinical Electrophysiology, May 2023. Bench testing or pre-clinical study results may not necessarily be indicative of clinical performance. N=12 in a pre-clinical canine study.
- Wagner et al., Biomaterials Science: An Introduction to Materials in Medicine, 4th Edition, 2020.
- Boston Scientific Data on file.
- Bench study performed under CT by Boston Scientific. Data on file.